- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN Recommends Only One Test for Breast Cancer, Says Expert
According to Dr Amy Cyr from the Siteman Cancer Center at Washington University in St. Louis, Missouri, while Oncotype DX is both prognostic and predictive, none of the other tests currently available have shown both capabilities.
The National Comprehensive Cancer Network (NCCN) only endorses one genomic test for use in patients with early-stage breast cancer, according to a presenter here at the NCCN 20th Annual Conference.
Oncotype DX, a 21-gene assay from Genomic Health, has won that honor, said presenter Amy Cyr, MD, from the Siteman Cancer Center at Washington University in St. Louis, Missouri.
In short, Oncotype DX is both prognostic and predictive.
The ability to predict response to treatment "is what, so far, makes this test stand out," she said.
Link to the report on Medscape:
The test serves two functions. In addition to providing a prognosis, the test has "some prediction capabilities in terms of therapy; it actually predicts a response to chemotherapy, compared with no chemotherapy," she explained.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
